+87.8%
MET vs GSK
+43.9%
+43.9%
-35.1%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.5% | -1.2% | +1.7% | +0.7% |
| 7D | 0.0% | -1.1% | +1.1% | +0.3% |
| 30D | +3.4% | +7.8% | -4.5% | +1.8% |
| 3M | +7.0% | +0.3% | +6.7% | +6.8% |
| 6M | +34.6% | +3.4% | +31.2% | +33.5% |
| YTD | +34.0% | +5.9% | +28.0% | +31.7% |
| 1Y | +35.9% | +8.2% | +27.7% | +33.1% |
| 3Y | +85.5% | +65.3% | +20.2% | +60.4% |
| 5Y | +87.8% | +43.3% | +44.4% | +63.9% |
| All | +87.8% | +43.9% | +43.9% | +63.9% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling